Micelle specialist issues updated financials detailing losses

Nurish.me sells finished a line of finished products based largely on a micellular encapsulation technology developed by company founder and chief science officer Michal Hegar, PhD, during his work at the University of Utrecht in the Netherlands​​.  The resulting ingredient, called CoreCumin, is a bioavailability-enhanced version of curcumin.  The company sells a line of liquid products based on that ingredient. 

 As of May of this year, when Hegar spoke with NutraIngredients-USA, the company was also offering it as an ingredient to other companies. Nurish.me also sells a cognitive support finished product in powder form.

According to the new financial statements for fiscal 2017 and 2018, which were posted Sunday, Nurish.me had no revenue in 2017 and posted $73,516 in revenue in 2018.  The company posed a net loss of $480,049 in 2017 and $968,259 in 2018.

"The continuing support of our shareholders and investors has allowed us to raise more than $3.4 million in equity and debt since May 2017, which has been partly utilized to develop clinically proven formulations that have been tested by five independent third-party analytical firms for their safety, purity, and integrity.  In addition, funding was allocated to optimize our proprietary nanotechnology platform,”​ said CEO David Perez.

Nurish.me is a division of a company called Altavoz Entertainment.  The stock trades in the penny realm at 50 cents a share.